Foghorn Therapeutics Inc.

NasdaqGM:FHTX 주식 보고서

시가총액: US$435.9m

Foghorn Therapeutics 관리

관리 기준 확인 3/4

Foghorn Therapeutics CEO는 Adrian H. Gottschalk, May2017 에 임명되었습니다 의 임기는 7.5 년입니다. 총 연간 보상은 $ 2.50M, 23.1% 로 구성됩니다. 23.1% 급여 및 76.9% 보너스(회사 주식 및 옵션 포함). 는 $ 4.01M 가치에 해당하는 회사 주식의 0.92% 직접 소유합니다. 4.01M. 경영진과 이사회의 평균 재임 기간은 각각 1.2 년과 7.3 년입니다.

주요 정보

Adrian H. Gottschalk

최고 경영자

US$2.5m

총 보상

CEO 급여 비율23.1%
CEO 임기7.5yrs
CEO 소유권0.9%
경영진 평균 재임 기간1.2yrs
이사회 평균 재임 기간7.3yrs

최근 관리 업데이트

Recent updates

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 07
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk

Oct 22
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

Sep 01
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

Jul 17
Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

May 09
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Apr 12
Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Feb 22
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Dec 13
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Nov 07
Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Jun 14
Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Foghorn Therapeutics: Selling For Less Than Cash Value

Oct 10

Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286

Aug 23

Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M

Aug 09

Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity

Jun 02

We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Apr 13
We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?

Feb 27
Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?

CEO 보상 분석

Adrian H. Gottschalk 의 보수는 Foghorn Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$91m

Jun 30 2024n/an/a

-US$86m

Mar 31 2024n/an/a

-US$93m

Dec 31 2023US$3mUS$579k

-US$98m

Sep 30 2023n/an/a

-US$103m

Jun 30 2023n/an/a

-US$115m

Mar 31 2023n/an/a

-US$112m

Dec 31 2022US$5mUS$575k

-US$109m

Sep 30 2022n/an/a

-US$109m

Jun 30 2022n/an/a

-US$109m

Mar 31 2022n/an/a

-US$105m

Dec 31 2021US$4mUS$540k

-US$101m

Sep 30 2021n/an/a

-US$93m

Jun 30 2021n/an/a

-US$85m

Mar 31 2021n/an/a

-US$78m

Dec 31 2020US$3mUS$479k

-US$69m

Sep 30 2020n/an/a

-US$63m

Jun 30 2020n/an/a

-US$58m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$1mUS$465k

-US$51m

보상 대 시장: Adrian H. 의 총 보상 ($USD 2.50M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 2.14M ).

보상과 수익: Adrian H. 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Adrian H. Gottschalk (48 yo)

7.5yrs

테뉴어

US$2,503,942

보상

Mr. Adrian H. B. Gottschalk serves as President, Chief Executive Officer and a Director of Foghorn Therapeutics Inc. since May, 2017. Prior to joining Foghorn and since 2004, Mr. Gottschalk worked at Bioge...


리더십 팀

이름위치테뉴어보상소유권
Adrian H. Gottschalk
President7.5yrsUS$2.50m0.92%
$ 4.0m
Steven Bellon
Chief Scientific Officer2.8yrsUS$1.19m0.27%
$ 1.2m
Alfonso Cardama
Chief Medical Officer1.2yrsUS$1.84m데이터 없음
Gerald Crabtree
Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Kristian Humer
Chief Financial Officerless than a year데이터 없음데이터 없음
Karin Hellsvik
Chief of Staff to the CEOno data데이터 없음데이터 없음
Michael LaCascia
Chief Legal Officer4yrsUS$1.99m0%
$ 0
Saurabh Sewak
Vice President of Corporate Development2.8yrs데이터 없음데이터 없음
Carlos Costa
Chief People Officerno data데이터 없음데이터 없음
Anna Rivkin
Chief Business Officerless than a year데이터 없음데이터 없음
Michael Garcia-Webb
VP & Chief of Staff Researchless than a year데이터 없음데이터 없음

1.2yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: FHTX 의 관리팀은 경험 (평균 재직 기간 1.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.


이사회 구성원

이름위치테뉴어보상소유권
Adrian H. Gottschalk
President7.5yrsUS$2.50m0.92%
$ 4.0m
Gerald Crabtree
Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
B. Parshall
Independent Director2.3yrsUS$157.65k0%
$ 0
Balkrishan Gill
Independent Director7.3yrsUS$159.07k0.061%
$ 267.0k
Douglas Cole
Founder & Independent Chairman of the Board9.1yrsUS$184.57k0%
$ 0
Charles Sawyers
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
David Schenkein
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Anthony Kouzarides
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Adam Koppel
Independent Director7.3yrsUS$153.07k0%
$ 0
Michael Mendelsohn
Independent Director7.6yrsUS$154.57k0%
$ 0
Scott Biller
Independent Director4.8yrsUS$145.57k0%
$ 0
Cigall Kadoch
Member of Scientific Advisory Board2.2yrsUS$252.52k6.52%
$ 28.4m

7.3yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: FHTX 의 이사회경험(평균 재직 기간 7.3 년)으로 간주됩니다.